<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05088811</url>
  </required_header>
  <id_info>
    <org_study_id>HCC medical research institute</org_study_id>
    <nct_id>NCT05088811</nct_id>
  </id_info>
  <brief_title>The Role of Long Non-coding RNAs WRAP53 and UCA-1 as Potential Biomarkers in Diagnosis of Hepatocellular Carcinoma</brief_title>
  <official_title>The Role of Long Non-coding RNAs WRAP53 and UCA-1 as Potential Biomarkers in Diagnosis of Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexandria University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexandria University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this work is to study the role of long non-coding RNAs WRAP53 and urothelial&#xD;
      carcinoma-associated 1 (UCA1) as potential biomarkers in diagnosis of hepatocellular&#xD;
      carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sample size calculation was done in department of medical statistics, Medical Research&#xD;
      Institute, Alexandria University and the total minimal sample size was calculated.&#xD;
&#xD;
      A prospective case control study will be conducted on 80 subjects divided into three groups:&#xD;
&#xD;
      Group (1): Thirty patients having liver cirrhosis and hepatocellular carcinoma diagnosed by&#xD;
      tripahsic CT.&#xD;
&#xD;
      Group (2): Thirty liver cirrhosis patients without hepatocellular carcinoma diagnosed by&#xD;
      abdominal ultrasound examination.&#xD;
&#xD;
      Group (3): Twenty normal subjects (control group) matching in age and sex with patients in&#xD;
      groups 1 and 2.&#xD;
&#xD;
      Patients will be recruited from the outpatient clinics and inpatient wards of Alexandria Main&#xD;
      University Hospital and Medical Research Institute Hospital. Full informed consent will be&#xD;
      taken from the patients and approval of the ethical committee of the Faculty of Medicine will&#xD;
      be fulfilled. Exclusion criteria: Patients with any inflammatory diseases or other&#xD;
      malignancies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 21, 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic value of long non coding RNA UCA-1 and WRAP53 in Hepatolcellular carcinoma</measure>
    <time_frame>One year</time_frame>
    <description>Calculating sensitivity and specifity of UCA-1 and WRAP53 to assess their diagnostic value in diagnosis of hepatocellular carcinoma</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Liver Cirrhosis</condition>
  <condition>Diagnoses Disease</condition>
  <arm_group>
    <arm_group_label>Liver cirrhosis</arm_group_label>
    <description>Group (1): Thirty patients having liver cirrhosis and hepatocellular carcinoma diagnosed by tripahsic CT.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hepatocellular Carcinoma</arm_group_label>
    <description>Group (2): Thirty liver cirrhosis patients without hepatocellular carcinoma diagnosed by abdominal ultrasound examination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Group (3): Twenty normal subjects (control group) matching in age and sex with patients in groups 1 and 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>WRAP53, UCA-1</intervention_name>
    <description>Diagnostic value of UCA-1 and WRAP53 in HCC</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Hepatocellular Carcinoma</arm_group_label>
    <arm_group_label>Liver cirrhosis</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum specimen&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Group (1): Thirty patients having liver cirrhosis and hepatocellular carcinoma diagnosed by&#xD;
        tripahsic CT.&#xD;
&#xD;
        Group (2): Thirty liver cirrhosis patients without hepatocellular carcinoma diagnosed by&#xD;
        abdominal ultrasound examination.&#xD;
&#xD;
        Group (3): Twenty normal subjects (control group) matching in age and sex with patients in&#xD;
        groups 1 and 2.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any subject without any of the exclusion criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with any inflammatory diseases or other malignancies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ahmed Elsheaita, Msc</last_name>
    <phone>+201062099085</phone>
    <email>A_mohamed200690@alexmed.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Alexandria University, faculty of medicine</name>
      <address>
        <city>Alexandria</city>
        <zip>21311</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amira Eid, MD</last_name>
      <email>Amira.eid@alexmed.edu.eg</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alexandria University, medical research institute</name>
      <address>
        <city>Alexandria</city>
        <zip>21561</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amal Ghanem, MD</last_name>
      <email>mri-dean@alexu.edu.eg</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <results_reference>
    <citation>Kamel MM, Matboli M, Sallam M, Montasser IF, Saad AS, El-Tawdi AHF. Investigation of long noncoding RNAs expression profile as potential serum biomarkers in patients with hepatocellular carcinoma. Transl Res. 2016 Feb;168:134-145. doi: 10.1016/j.trsl.2015.10.002. Epub 2015 Oct 24.</citation>
    <PMID>26551349</PMID>
  </results_reference>
  <results_reference>
    <citation>Pouladi N, Abdolahi S, Farajzadeh D, Hosseinpour Feizi MA. Haplotype and linkage disequilibrium of TP53-WRAP53 locus in Iranian-Azeri women with breast cancer. PLoS One. 2019 Aug 6;14(8):e0220727. doi: 10.1371/journal.pone.0220727. eCollection 2019.</citation>
    <PMID>31387111</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang F, Ying HQ, He BS, Pan YQ, Deng QW, Sun HL, Chen J, Liu X, Wang SK. Upregulated lncRNA-UCA1 contributes to progression of hepatocellular carcinoma through inhibition of miR-216b and activation of FGFR1/ERK signaling pathway. Oncotarget. 2015 Apr 10;6(10):7899-917.</citation>
    <PMID>25760077</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 21, 2021</study_first_submitted>
  <study_first_submitted_qc>October 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2021</study_first_posted>
  <last_update_submitted>October 9, 2021</last_update_submitted>
  <last_update_submitted_qc>October 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Alexandria University</investigator_affiliation>
    <investigator_full_name>Elsheaita, Ahmed Mohamed Elmoughazy Abdelfatah Aly</investigator_full_name>
    <investigator_title>Assistant lecturer, experimental and clinical internal medicine, medical research institute</investigator_title>
  </responsible_party>
  <keyword>Hcc, liver cirrhosis, UCA-1, WRAP53</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

